Clinical Trials Directory

Trials / Terminated

TerminatedNCT00830245

A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Clinical Research Center for Solid Tumor, Korea · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To assess the efficacy and safety of erlotinib for non-small cell lung cancer patients with leptomeningeal carcinomatosis

Conditions

Interventions

TypeNameDescription
DRUGErlotinibErlotinib 150mg/day

Timeline

Start date
2009-01-01
Primary completion
2011-07-01
Completion
2011-07-01
First posted
2009-01-27
Last updated
2011-07-26

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT00830245. Inclusion in this directory is not an endorsement.